Overview

Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.
Phase:
Phase 2
Details
Lead Sponsor:
QOL Medical, LLC